Efficacy and safety of corticosteroid and immunosuppressive agent combination therapy for pediatric IgA nephropathy: a meta-analysis

TL;DR

This study finds that combining corticosteroids with immunosuppressive drugs is more effective than using corticosteroids alone for treating pediatric IgA nephropathy, without increasing side effects.

Contribution

The study provides a meta-analysis comparing corticosteroid monotherapy with combination therapies in pediatric IgA nephropathy.

Findings

Combination therapies like tacrolimus + GC and MMF + GC significantly reduce proteinuria compared to GC alone.

Only MMF + GC significantly improves hematuria compared to GC monotherapy.

No significant differences in adverse events were found between treatment groups.

Abstract

IgA nephropathy (IgAN) is a common primary glomerular disease in children. The efficacy and safety of glucocorticoid (GC) and immunosuppressive therapies remain debated. This study aimed to evaluate their clinical effectiveness and safety in pediatric IgAN.

A systematic search was conducted in six databases (PubMed, Web of Science, Cochrane, Embase, CNKI, Wanfang, and VIP), yielding 404 studies, of which eight met inclusion criteria. Eligible studies included RCTs or retrospective studies involving pediatric patients (≤18 years) treated with immunosuppressants plus GC. Outcomes assessed included proteinuria, hematuria, serum creatinine, and adverse events. Two researchers independently extracted and analyzed data. Network meta-analysis (NMA) was performed using R software, incorporating network plots, forest plots, and SUCRA rankings.

Network topology showed strong links between GC monotherapy and regimens such as “tacrolimus + GC” and “mycophenolate mofetil (MMF) + GC.” SUCRA rankings indicated superior efficacy of combination therapies in reducing proteinuria and hematuria. Forest plots revealed that all combination regimens significantly reduced proteinuria compared to GC alone (P < 0.05), with only MMF + GC significantly improving hematuria (P < 0.05). No significant differences in adverse event rates were found among treatment groups (P > 0.05). Funnel plots suggested minimal publication bias.

Combination therapies, especially tacrolimus + GC and MMF + GC, offer greater efficacy than GC monotherapy in pediatric IgAN, without increasing adverse events. These findings support their clinical application, though larger studies are needed to validate results and optimize treatment strategies.

Figures